文献速递临床试验与 GCP基础与转化研究

高剂量与低剂量维生素D补充对重型颅脑损伤患者炎症因子及死亡率疗效的随机安慰剂对照试验方案

Efficacy of high-dose versus low-dose vitamin D supplementation on serum levels of inflammatory factors and mortality rate in severe traumatic brain injury patients: study protocol for a randomized placebo-controlled trial.
PubMed 文献 · Trials · 2020-07-29

本研究为随机安慰剂对照试验方案,拟纳入74例18-65岁伊朗颅脑损伤成人,每日分别口服维生素D补充剂(100,000 IU滴剂)或相似安慰剂(1000 IU)共5天,旨在评估高剂量维生素D对炎症因子水平和死亡率的影响。若证实可降低炎症细胞因子,将为后续多中心临床试验提供依据,并可能通过减轻炎症和感染相关并发症改善颅脑损伤患者临床结局。

要点

  • 纳入74例18-65岁颅脑损伤成人,随机接受每日10万IU维生素D或1000IU安慰剂共5天。
  • 主要关注炎症因子水平变化及死亡率,探索高剂量维生素D的免疫调节作用。
  • 维生素D补充剂廉价安全,若有效可能改善颅脑损伤患者炎症与感染相关结局。

核心结论

  • 该试验方案拟验证高剂量维生素D补充能否降低重型颅脑损伤患者炎症细胞因子水平及死亡率。
  • 若观察到炎症细胞因子下降,将为开展多中心临床试验评估维生素D在神经重症患者中的疗效提供证据。
  • 因维生素D补充剂廉价且安全,该试验有望通过减轻炎症和感染相关并发症改善颅脑损伤患者临床结局。

研究设计与样本

  • 随机安慰剂对照试验,计划纳入74例18-65岁伊朗颅脑损伤成人。
  • 干预组每日口服维生素D补充剂100,000 IU滴剂,对照组每日口服相似安慰剂1000 IU,均持续5天。
  • 试验已在伊朗临床试验注册中心注册(IRCT20180619040151N3),注册日期2019年8月10日。

临床怎么用

  • 该方案尚处于试验阶段,暂不能据此改变颅脑损伤患者的维生素D补充临床实践。
  • 若试验证实可降低炎症细胞因子,可能为神经重症患者补充维生素D提供循证依据。

局限性

  • 原文为试验方案,尚未报告实际干预结果与疗效数据。
  • 样本量74例,研究结果的外推需后续多中心临床试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traumatic brain injury (TBI) is the most common trauma worldwide and is a leading cause of injury-related death and disability. Inflammation is initiated as a result of the TBI, which is in association with severity of illness and mortality in brain trauma patients, especially in subdural hemorrhage and epidural hemorrhage cases. A high percentage of adults admitted to the intensive care unit with TBI are diagnosed with vitamin D deficiency; this deficiency may induce impaired immune responses and increase the risk of infections. Vitamin D intervention has been shown to modulate pro- and anti-inflammatory cytokines in non-critically ill patients, but to date, there is no substantial data on the effectiveness of vitamin D for the improvement of immune function in traumatic brain injury patients. METHODS/DESIGN: A randomized clinical trial (RCT) will be performed on 74 Iranian adults 18-65 years old with brain trauma and will be treated daily with vitamin D supplements (100,000 IU oral drop) or a similar placebo (1000 IU) for 5 days. DISCUSSION: If this randomized clinical trial demonstrates reductions in inflammatory cytokines, it would provide evidence for a multicenter clinical trial to evaluate the efficacy of vitamin D supplementation in neurocritically ill patients. Since vitamin D supplements are inexpensive and safe, this clinical trial could have the potential to improve clinical outcomes in traumatic brain injury patients through reduction of inflammation and infection-associated morbidity and mortality rates. TRIAL REGISTRATION: Iranian Registry of Clinical Trials, IRCT20180619040151N3 . Registered on 10 August 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Arabi SM, Sedaghat A, Ehsaei MR, et al. Efficacy of high-dose versus low-dose vitamin D supplementation on serum levels of inflammatory factors and mortality rate in severe traumatic brain injury patients: study protocol for a randomized placebo-controlled trial. Trials. 2020. PMID: 32727558. doi:10.1186/s13063-020-04622-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。